| 摘要 |
The invention relates to theurapetic approaches characterised by the use of rapamycin/sirolimus and SHIGA-LIKE toxin acting against the cancer of prostate, the benign hyperplasia appeared to the urologic tract (kidneys, prostate, testicles, related lymphadens, ureter etc) as well as against to lymphoid tissues (liquid or compact) in general. The herein proposed tubular spring (stent) will produce known mechanic properties; being enriched with rapamycin/sirolymus or/and shiga toxin, said stent will exhibit further immunostimulation properties. Use of the rapamycin for depiction of the tumorous dynamic, for pharmaceutical action (medicament carrier) on lymphoid tissues as well as for use in whatever form (in its identical form, in the form of an orally-administrated liquid, alone or connected, as a coating medium etc) in the aforementioned urologic fields. |
